Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Randomized study evaluating optimal dose, efficacy, and safety of E7386 ...
E7386 | CBP/beta-catenin Inhibitor | CAS 1799824-08-0 | Selleck Chemicals
E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models ...
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in ...
E7386 in patients with advanced solid tumors: results from the dose ...
Study of E7386 and Lenvatinib for Patients with Liver, Colon ...
E7386 + Pembrolizumab for Solid Cancers Clinical Trial 2025 | Power
Study of E7386 and Pembrolizumab for Patients with Previously Treated ...
Optimización de dosis con E7386 + levatinib para carcinoma endometrial
E7386 for Advanced Cancer Clinical Trial 2024 | Power
E7386 + Lenvatinib for Solid Cancer Clinical Trial 2024 | Power
Badanie E7386 w połączeniu z innymi lekami przeciwnowotworowymi u ...
(PDF) Different types of reactions to E7386 among colorectal cancer ...
Estudio de E7386 y Pembrolizumab en Pacientes con Tumores Sólidos ...
E-7386 | CBP/beta-catenin Modulator | MedChemExpress
E-7386 | Epigenetic Reader Domain | TargetMol
E7386, a Selective Inhibitor of the Interaction between β-Catenin and ...
E-7386 (E7386) | Wnt-β-catenin inhibitor | Probechem Biochemicals
Oncology Letters
Wnt Pathway: An Integral Hub for Developmental and Oncogenic Signaling ...
A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin ...
【E7386+Lenvatinib】進行性固形がん / 第I相試験 / CBP-βカテニン阻害薬 / マルチキナーゼ阻害薬 | 国立がん研究 ...
【E7386】進行性固形がん / 第I相試験 / CBP-βカテニン阻害薬 | 国立がん研究センター中央病院 先端医療科 – 国立がん研究 ...
切除不能な肝細胞癌にCBP/β-カテニン阻害薬E7386とレンバチニブの併用療法が有望【ASCO 2023】：日経メディカル
Phase 1 clinical research results of E7386, Jointly Created by ...
Abstract 2026: Single-cell RNA-sequencing analysis of tumor endothelial ...
切除不能な肝細胞癌にCBP/β-カテニン阻害薬E7386とレンバチニブの併用療法が有望【ASCO 2023】：がんナビ
エーザイとPRISM BioLab共同創製のCBP/β-catenin阻害剤E7386について、臨床におけるPOC（Proof of ...
Abstract 1830: E7386, a selective inhibitor of the interaction between ...
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by ...
E7386, a selective inhibitor of the interaction between β-catenin and ...
The β-catenin C terminus links Wnt and sphingosine-1-phosphate ...
β-catenin/CBP activation of mTORC1 signaling promotes partial ...
CBP/β-catenin阻害薬E7386とペムブロリズマブを併用する固形癌対象のフェーズ1b/2を開始：日経メディカル
Role of β-Catenin Activation in the Tumor Immune Microenvironment and ...
Study of a New Drug, E7386, in Combination with Lenvatinib in People ...
Enhanced β-catenin/p300 signaling in long-term hematopoietic stem cells ...
Cancers | Free Full-Text | Differentiation Therapy Targeting the β ...
Advances in the development of Wnt/β-catenin signaling inhibitors - PMC
Specific inhibition of CBP/β-catenin interaction rescues defects in ...
Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha ...
The diverse mechanisms of BCL9 independent of canonical Wnt-signaling ...
Molecular pathways in the development of HPV-induced cervical cancer - PMC
PRISM BioLab[206A]：PRISM BioLabとエーザイが共同創出したE7386、ESMO OPEN 誌にて第I相臨床試験結果 ...
PRISMBio---反発、E7386とレンバチニブメシル酸塩との併用試験の結果が「欧州臨床腫瘍学会年次総会」で発表へ | 株探ニュース
Eli Lilly’s Novel Investigational Antibody Drug Conjugate Demonstrates ...
PRISM BioLab[206A]：PRISM BioLabとエーザイが共同創出したE7386、エーザイが米国臨床腫瘍学会（ASCO）年次 ...
Targeting CBP and p300: Emerging Anticancer Agents
切除不能HCCへのE7386とレンバチニブの併用療法のコンセプトの正しさが臨床試験検体のバイオマーカー解析から示唆【ASCO GI 2024 ...
PRISM BioLab[206A]：PRISM BioLab とエーザイが共同創出したE7386、Clinical Cancer ...
Monitoring Interactions and Dynamics of Endogenous Beta-catenin With ...
β-catenin activation down-regulates cell-cell junction-related genes ...
PRISM BioLab[206A]：PRISM BioLabとエーザイが共同創出したE7386、エーザイが欧州臨床腫瘍学会（ESMO）年次 ...
E-7386 - Epigenetic Reader Domain
β-catenin interacted with CBP and had a synergic effect on lung cancer ...
Wnt/β-catenin/CBP signaling maintains long-term murine embryonic stem ...
PRISMバが反発、エーザイと共同創出した「E7386」の臨床試験結果が欧州臨床主要学会で発表 - ライブドアニュース
MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes ...
